The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma

[1]  Michael D. Robbins,et al.  Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma , 2018, The New England journal of medicine.

[2]  M. Dimopoulos,et al.  Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial. , 2018 .

[3]  J. Fay,et al.  Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. , 2017, Blood.

[4]  M. Boccadoro,et al.  Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma , 2017, Expert Review of Anticancer Therapy.

[5]  M. Mehra,et al.  Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD. , 2016, The oncologist.

[6]  Carlos Ortiz-de-Solorzano,et al.  The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care , 2016, Clinical Cancer Research.

[7]  G. Caponigro,et al.  Abstract 4630: The pan-PIM inhibitor PIM447 enhances the antitumor activity of lenalidomide in multiple myeloma cells via synergistic inhibition of c-MYC , 2016 .

[8]  Alex M. Fichtenholtz,et al.  Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. , 2016, Blood.

[9]  S. Jagannath,et al.  Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. , 2016, Blood.

[10]  A. Kassim,et al.  Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity , 2016, Bone Marrow Transplantation.

[11]  Yumin Dai,et al.  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies. , 2015, Journal of medicinal chemistry.

[12]  J. Tamburini,et al.  Control of Pim2 kinase stability and expression in transformed human haematopoietic cells , 2015, Bioscience reports.

[13]  M. Raab,et al.  Targeting the Pim kinases in multiple myeloma , 2015, Blood Cancer Journal.

[14]  J. Laubach,et al.  Management of relapsed multiple myeloma after autologous stem cell transplant. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  W. Klapper,et al.  Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study , 2015, Haematologica.

[16]  M. Dimopoulos,et al.  Current treatment landscape for relapsed and/or refractory multiple myeloma , 2015, Nature Reviews Clinical Oncology.

[17]  A. Khwaja,et al.  PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways , 2014, British journal of haematology.

[18]  H. Handa,et al.  Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.

[19]  Allan Wu,et al.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. , 2014, Blood.

[20]  Audrey Kauffmann,et al.  Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers , 2014, Clinical Cancer Research.

[21]  Christopher J. Ott,et al.  The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.

[22]  R. Orlowski,et al.  Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. , 2013, Clinical lymphoma, myeloma & leukemia.

[23]  Jianjun Yu,et al.  Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. , 2013, Blood.

[24]  A. Kraft,et al.  Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice , 2013, Journal of Hematology & Oncology.

[25]  P. L. Bergsagel,et al.  Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.

[26]  Varsha Gandhi,et al.  Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. , 2011, Blood.

[27]  I. Endo,et al.  The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells , 2011, Leukemia.

[28]  M. Nawijn,et al.  For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.

[29]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[30]  J. Blenis,et al.  Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.

[31]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[32]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[33]  D. Esseltine,et al.  Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. , 2005, Blood.

[34]  B. Farmer,et al.  Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase. , 2005, Acta crystallographica. Section F, Structural biology and crystallization communications.

[35]  Jos Jonkers,et al.  Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.

[36]  L. Chodosh,et al.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.

[37]  Anton Berns,et al.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.

[38]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[39]  A. Berns,et al.  Proviral tagging in E mu‐myc transgenic mice lacking the Pim‐1 proto‐oncogene leads to compensatory activation of Pim‐2. , 1995, The EMBO journal.

[40]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[41]  Wim Quint,et al.  Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.